Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Esophageal Squamous Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Ruijin hospital, Shanghai jiaotong university school of medicine, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Shengguang Zhao)
Contact: Principal Investigator (Shengguang Zhao)
Shuyan Li (Sub-investigator)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Sub-study 1 Cervical Cancer (Volrustomig Monotherapy) · Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy) · Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)

Abroad (travel likely)RecruitingPHASE2

Los Angeles, United States · Baltimore, United States

Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma · Neoadjuvant Therapy

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Fuzhou, China

Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE3

Tianjin, China